Markets

SPY735.29▲ +0.31%QQQ656.10▲ +1.40%DIA512.22▼ -0.40%GLD372.52▼ -0.79%TLT81.92▼ -0.01%BABA109.45▲ +1.28%NIO3.39▲ +5.94%PDD83.03▼ -1.10%Realtime derived data

$HALO

Independent coverage

103.63▼ −15.72%realtime derived

Independent research

Latest Research

Latest · 2026-11-06

Independent Researchsingle-name-earnings Earnings Results Data Desk2026-11-06

Halozyme Therapeutics quarterly revenue jumps 39.2% to $493.0 million

Halozyme Therapeutics' revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 5, 2026.

$HALO Octans Research

Coverage Timeline

2026-11-06

2026-11-06Halozyme Therapeutics quarterly revenue jumps 39.2% to $493.0 million

Halozyme Therapeutics quarterly revenue jumps 39.2% to $493.0 million→

Halozyme Therapeutics quarterly revenue jumps 39.2% to $493.0 million